Table 3.
Overall Association of Indoleamine-2,3-Dioxygenase-2 Genotypes to Thomas Jefferson University vs Control Cohorts
| R248 (WT) | R248W (hetero-) |
R248W (homo-) |
Y359 (WT) | Y359Stop (hetero-) |
Y359Stop (homo-) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|||||||
| IDO2 genotype | n | % | n | % | n | % | n | % | n | % | n | % |
| TJUH cohort, n = 79 | 25 | 32 | 39 | 49 | 15 | 19 | 52 | 66 | 19 | 24 | 8 | 10 |
|
| ||||||||||||
| TJUH FPC cohort, n = 15 | 6 | 40 | 4 | 27 | 5 | 33 | 7 | 46 | 4 | 27 | 4 | 27 |
|
| ||||||||||||
| CEU control cohort, n = 99 | 26 | 27 | 44 | 44 | 29 | 29 | 54 | 55 | 38 | 38 | 7 | 7 |
CEU, Utah residents with northern and western European ancestry; FPC, familial pancreatic cancer; Hetero-, heterozygous; Homo-, homozygous; IDO2, indoleamine-2,3-dioxygenase-2; TJUH, Thomas Jefferson University Hospital; WT, wild-type.